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A randomised controlled trial of increasing fruit
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carotenoid concentration and activities of PON-1
and LCAT in HDL from subjects with type 2
diabetes
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Abstract
Background: High density lipoproteins (HDL) have many cardioprotective roles; however, in subjects with type 2
diabetes (T2D) these cardioprotective properties are diminished. Conversely, increased fruit and vegetable (F&V)
intake may reduce cardiovascular disease risk, although direct trial evidence of a mechanism by which this occurs in
subjects with T2D is lacking. Therefore, the aim of this study was to examine if increased F&V consumption influenced
the carotenoid content and enzymes associated with the antioxidant properties of HDL in subjects with T2D.
Methods: Eighty obese subjects with T2D were randomised to a 1- or ≥6-portion/day F&V diet for 8-weeks. Fasting
serum was collected pre- and post-intervention. HDL was subfractionated into HDL2 and HDL3 by rapid ultracentrifugation.
Carotenoids were measured in serum, HDL2 and HDL3 by high performance liquid chromatography. The activity of
paraoxonase-1 (PON-1) was measured in serum, HDL2 and HDL3 by a spectrophotometric assay, while the activity of
lecithin cholesterol acyltransferase (LCAT) was measured in serum, HDL2 and HDL3 by a fluorometric assay.
Results: In the ≥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly
HDL3, (α-carotene, p = 0.008; β-cryptoxanthin, p = 0.042; lutein, p = 0.012; lycopene, p = 0.016), as did the activities of PON-1
and LCAT in HDL3 (p = 0.006 and 0.044, respectively).
Conclusion: To our knowledge, this is the first study in subjects with T2D to demonstrate that increased F&V intake
augmented the carotenoid content and influenced enzymes associated with the antioxidant properties of HDL. We
suggest that these changes would enhance the cardioprotective properties of this lipoprotein.
Clinical trial registration: ISRCTN21676269
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Background
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in Western societies, whose in-
cidence is augmented by T2D [1]. In 2008, diabetes was
the direct cause of 17% of all CVD related deaths [2].
Conversely, high density lipoproteins (HDL) are nor-
mally associated with reduced CVD risk, as these
lipoproteins have many antiatherogenic properties; in-
cluding their antioxidant and reverse cholesterol trans-
port (RCT) capabilities. Furthermore, HDL stimulates
glucose uptake and fatty acid oxidation, opposing insulin
resistance [3]. However, in subjects with T2D the
function of HDL may be defective, as hyperglycaemia
increases lipid peroxidation [4], while the release of
the inflammatory marker serum amyloid A (SAA) from
hypertrophic adipocytes also impacts on the anti-
inflammatory and antioxidant properties of HDL [5].
Thus the main enzymes associated with HDL’s antioxi-
dant function, paraoxonase-1 (PON-1) and lecithin chol-
esterol acyltransferase (LCAT), with this latter enzyme
also being involved in the maturation of HDL, may be
altered to a pro-atherogenic phenotype in dysfunctional
HDL [6,7].
Therefore, interventions that reduce the risk of dia-
betes and CVD, such as increased fruit and vegetable
(F&V) intake, are highly desirable. Although the rela-
tionship between F&V intake and the incidence of T2D
is not fully understood, there is substantial support for
increased intake to reduce diabetes and CVD risk. In
this regard, the study of Villegas et al. [8] reported that
vegetables were protective against the development of
T2D, while, in a population without diabetes, Panagiotakos
et al. [9] identified that subjects consuming vegetables
for more than 3 days per week had a 70% decreased
risk of CVD and, furthermore, that an increase of
one portion of fruit per day decreased CVD risk by
10%. In support of this, Cooper et al., [10] recently
showed that increased vegetable intake and a variety
of fruit reduced diabetes risk. Therefore, from the
above evidence, it appears that increased F&V intake
would be protective against the development of dia-
betes and the associated CVD complications.
The protective effect of F&V may be related to their
rich antioxidant content, as these have been linked to a
lower diabetes risk and the suppression of the inflamma-
tory response related to diabetes and CVD development
[11,12]. Many F&V derived lipid phase antioxidants,
such as the carotenoids, are transported in the circula-
tion by lipoproteins, including HDL, and in the case of
lycopene, has been shown to influence the cardioprotec-
tive properties of HDL. In fact, in a previous study by
our group we found that among middle-aged, moder-
ately overweight subjects, lycopene intake, via supple-
ment or as a lycopene-rich diet, lead to antiatherogenic
increases in the activities of PON-1 and LCAT within
HDL [11]. Additionally, another study identified that
serum carotenoids and the activity of serum-PON-1
increased following a Mediterranean-like diet, while
the inflammatory marker C-reactive protein (CRP) de-
creased [13]. Overall, these studies suggest that the anti-
oxidants within F&V may, in part, be responsible for
their cardioprotective effects.
However, although the literature is suggestive that in-
creased F&V intake is beneficial to subjects with T2D,
no study has investigated the relationship between in-
creased F&V intake and the enzymes associated with
HDL in these subjects. Therefore, the aim of this study
was to examine if increased F&V intake had the poten-
tial to enhance the antiatherogenic properties of this
lipoprotein in subjects with T2D.
Methods
Study population
This study was a secondary analysis of blood samples
collected from subjects with T2D following a rando-
mised controlled F&V intervention. The study consisted
of 80 subjects who were recruited from the diabetes out-
patient clinics at the Regional Centre for Endocrinology
and Diabetes at the Royal Victoria Hospital, Belfast, UK.
All subjects were obese (BMI > 30 kg/m2), and aged
between 40 and 70 years. In each case T2D was con-
trolled by diet or oral hypoglycaemic therapy, which was
maintained for the duration of the study. Prior to the
8-week intervention period all subjects underwent a
4-week run-in period, where they were asked to con-
sume 1-portion of F&V/day. One portion of F&V is de-
fined by the Food Standards Agency and the National
Health Service as 80 g [14]. Following this, subjects were
randomly assigned to 1 of 2 treatment groups (n = 40/
group): a low F&V group, where they continued to con-
sume 1-portion of F&V/day, or a high F&V group, were
they consumed ≥6-portions of F&V/day. Fasting blood
samples were obtained following the wash-out phase
(week-0) and post-intervention (week-8), serum was iso-
lated by centrifugation and stored in aliquots at −80°C
until required for analysis. Figure 1 illustrates the study
design for this intervention. F&V supplementation was
similar to that of a normal diet, therefore, did not pose
any health risk. Specific advice was also given to ensure
a similar calorific and macronutrient intake to their nor-
mal diet, while weekly contact encouraged compliance.
To assess compliance, two 7-day food diaries were
completed during the run-in period and during the
intervention (results not shown). Subjects selected the
F&Vs of their choice, which were delivered weekly from
a local supermarket during the 8-week intervention
period. They were also offered advice on suitable storage
and cooking methods for the F&Vs to minimise their
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degradation. This study was approved by the ethics com-
mittee of Queen’s University Belfast, and all subjects
gave written informed consent.
Exclusion criteria
Exclusion criteria included any acute coronary/cerebro-
vascular event, surgery within the previous 3-months;
pregnant or lactating females; oral anticoagulant therapy;
excess alcohol consumption (>2 units per day for fe-
males; >3 units per day for males); food sensitivities that
would interfere with the F&V consumption; medical
conditions or dietary restrictions that would substantially
limit the ability of the subject to complete the study re-
quirements; and ingestion of oral vitamin/antioxidant
supplements in the 4-weeks prior to the wash-out phase.
Isolation of HDL2 and HDL3 from serum
HDL2 and HDL3 were harvested from freshly thawed
serum by rapid ultracentrifugation, according to the
method of McPherson et al., (2007) [15]. This consisted
of a 3-step, 6-hour long procedure. HDL samples were
stored at −80°C and at this temperature HDL is stable
for up to one year (results not shown), all samples were
batch analysed.
Apolipoprotein (apo) AI concentration
Apo AI was determined by a single radial immunodiffu-
sion method, as previously described [16].
Carotenoid concentration
Lipid soluble carotenoids, including α-carotene, β-carotene,
β-cryptoxanthin, lutein, lycopene and zeaxanthin were
measured in serum, HDL2 and HDL3 by reverse-phase-
high performance lipid chromatography (HPLC) with diode
array detection, as previously described [17].
PON-1 activity
The arylesterase activity of PON-1 was measured in
serum, HDL2 and HDL3. This assay was based upon the
ability of PON-1 to hydrolyse phenylacetate, and was an
adaption of the method of Hasselwander et al., 1999
[18], utilising 5 μL of serum, 200 μL of HDL2 and 20 μL
of HDL3. One unit of arylesterase activity (U) is defined
as 1 μmol of phenol generated per minute [18].
LCAT activity
The activity of LCAT was measured in serum, HDL2
and HDL3 using a commercially available fluorometric
assay (RB-LCAT, ROAR Biomedical, NY, USA), as per
manufacturer’s instructions. The LCAT assay required
5 μL of serum, HDL2 or HDL3 per analysis.
hsCRP and SAA concentration
The concentration of serum high sensitive (hs)CRP was
determined by immunoturbidimetry. While SAA was
measured in serum, HDL2 and HDL3 by a commercially
available ELISA (Invitrogen, Human SAA KHA0011C)
and the analysis was performed on a Grifols TRITURUS
automated ELISA system (Italy), as per the manufac-
turer’s instructions, with the following modifications
prior to analysis: serum was diluted 1:150, HDL2 1:10
and HDL3 1:100.
Statistical analysis
A retrospective power calculation for HDL3-lycopene
and HDL3-PON-1 activity indicated that a subject popu-
lation of 20 per group was sufficient to give a 90% power
at the 5% level of significance to detect a statistical dif-
ference between the groups. However, for completeness
we have included all subjects in our analyses. Statistical
analyses were performed using SPSS Statistics version
17.0. Variables were assessed for normality and logarith-
mically transformed where required. Between-group
comparisons were analysed by an independent samples
t-test. Within-group comparisons were analysed by a
paired sample t-test. To adjust for potential confounders,
an analysis of covariance was conducted, with final value
of the variable of interest included as the dependent
variable, the initial value of the variable of interest in-
cluded as the covariate, and potential confounders, such
80 volunteers 
with T2D 
recruited
Run-in period 
(1 portion F&V/day)
n=40
(1 portion F&V/day)
n=40
(6 portions F&V/day)
Randomisation 
and assessment
Assessment
4 weeks 8 weeks
Figure 1 Study Design.
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as BMI, included in the model. All variables were sum-
marised as mean (SEM) when normally distributed and
as geometric mean (interquartile range) when normally
distributed after logarithmic transformation. Correla-
tions between variables were assessed by Pearson’s two-
tailed bivariate analysis. Significance was set as p < 0.05
for all analyses.
Results
Subject characteristics
Initially 98 subjects were recruited into the study, 17
subjects withdrew during the run-in period prior to ran-
domisation and 1 subject withdrew during the interven-
tion period due to a family bereavement. A total of 80
subjects with T2D completed the 8-week intervention
study. Six subjects had either pre- or post-intervention
serum hsCRP levels >10 mg/l and thus were excluded
from further analyses. This was in accordance with
American Heart Association guidelines [19] as a hsCRP
of >10 mg/l is taken as evidence of active infection or
inflammation. Thus 74 subjects were included in the
final analyses (Table 1). All baseline characteristics were
comparable between the groups (p > 0.05 for all compari-
sons), and although there were more women randomised
to the ≥6-portion intervention (n = 15/39) compared
to the number of women randomised to the 1-portion
intervention (n = 7/35), this was not statistically different
(p = 0.295). Following intervention, BMI was different
between the groups, which was driven by the significant
increase in BMI (0.3 kg/m2) following the ≥6-portion
intervention (p = 0.001). However, the effect of this change
in BMI was tested independently using an analysis of
covariance for all subsequent statistical analyses and
was found not to influence the results (data not shown).
Additionally, HbA1C decreased following the 1-portion
intervention (p = 0.032), although this was not continued
in the between group comparisons (p > 0.05).
Fruit and vegetable consumption
F&V intake was calculated from two 7-day food diaries,
where it was identified that F&V intake was significantly
different in the ≥6- vs. 1-portion comparisons (p ≤ 0.001)
following intervention, which was driven by the signifi-
cant increase in F&V intake following the ≥6-portion
intervention [pre 1.4 (0.5) portions F&V/day vs. post 5.2
(1.4) portions F&V/day, p ≤ 0.001], which equated to a
3.8 (1.34) portion increase in F&V/day, while F&V intake
did not change following the 1-portion intervention [pre
1.2 (0.4) portions F&V/day vs. post 1.5 (0.9) portions
F&V/day, p = 0.335].
Dietary intake
Following intervention, total energy was not different in
the ≥6- vs. 1-portion comparisons (p > 0.05; Table 2).
However, carbohydrate and total sugar were significantly
different between the groups (p < 0.05 and p ≤ 0.001,
respectively), which were driven by the significant
increase following the ≥6-portion intervention (p < 0.05
and p ≤ 0.001, respectively).
Apo AI concentration
Following intervention, apo AI was not different in the
between or within group comparisons (p > 0.05 for all
comparisons, results not shown).
Table 1 Subject characteristics pre and post intervention
Characteristic 1 Portion Group (n=35) 6 Portion Group (n=39) Trend for change
Pre Post Pre Post between groups
Male Sex (%) 80 - 61.5 - 0.295
BMI (kg/m2) 30.1 (0.6) 30.1 (0.7) 30.7 (0.6) 31.0 (0.6)d 0.012
Age (years) 59.9 (1.23) - 58.2 (1.47) - 0.263
Glucose (mmol/L) 8.0 (6.6,9.6) 8.5 (7.5,22.3) 8.2 (7.0,8.9) 8.9 (8.3,18.8) 0.587
Insulin (mU/L) 13.7 (9.4,21.2) 14.6 (7.5,22.3) 11.9 (8.0,17.4) 16.8 (8.3,18.8) 0.470
HbA1C (%) 7.2 (0.2) 7.1 (0.2)c 7.1 (0.2) 7.1 (0.2) 0.068
Duration of diabetes (years) 6.7 (0.9) - 5.2 (0.7) - >0.05
Triglycerides (mmol/L) 1.82 (1.2,2.1) 1.69 (1.1,2.1) 1.73 (1.1,2.0) 1.79 (1.2,2.2) 0.168
Total cholesterol (mmol/L) 3.95 (0.13) 3.86 (0.11) 3.87 (0.12) 3.93 (0.12) 0.640
HDL cholesterol (mmol/L) 1.24 (0.05) 1.20 (0.05) 1.25 (0.05) 1.23 (0.05) 0.194
Lipid lowering therapy (%) 94 - 95 - >0.05
Diabetic therapy (diet) (%) 5 - 8 - >0.05
Oral hypoglycaemic therapy (%) 86 - 80 - >0.05
Results expressed as mean (SD) or when data was not normally distributed as geometric mean (interquartile range).
The following subscripts indicate - a; p≤0.05 for baseline comparison between groups: b; p≤0.001 for baseline comparison between groups: c: p≤0.05 for within
group comparison: d; p≤0.001 for within group comparison.
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Carotenoid concentration
Following intervention, serum α-carotene, β-cryptoxan-
thin, lutein and zeaxanthin increased in the ≥6- vs.
1-portion comparisons (p < 0.05 for all comparisons);
Table 3) which were driven by increases of ~8% in α-
carotene (p = 0.036), ~25% β-cryptoxanthin (p = 0.001)
and ~25% lutein (p = 0.003), and the borderline non-
significant increase in zeaxanthin (p = 0.067) following
the ≥6-portion intervention. In HDL2, β-cryptoxanthin
increased in the ≥6- vs. 1-portion post-intervention
comparisons (p < 0.05), which was driven by the ~47%
increase in β-cryptoxanthin (p = 0.015) following the ≥
6-portion intervention, additionally, lutein also in-
creased in HDL2 following the ≥6-portion intervention
(p ≤ 0.001). For HDL3, α-carotene, β-cryptoxanthin,
lutein and lycopene increased in the ≥6- vs. 1-portion
post-intervention comparisons (p < 0.05 for all com-
parisons), which were driven by an increase of ~38%
α-carotene (p = 0.001), ~32% β-cryptoxanthin (p =
0.041), ~9% lutein (p = 0.006) and ~27% lycopene
(p = 0.015) following the ≥6-portion intervention.
Additionally, following the ≥6-portion intervention
there was a ~30% increase in β-carotene (p = 0.012) and
a ~11% increase in zeaxanthin (p = 0.004).
Table 2 Total energy intake and macronutrient intake pre and post F&V intervention
1 Portion (n = 35) 6 Portions (n = 39) Trend for change
Pre Post Pre Post between groups
Energy (kcal/day) 1601 (370) 1646 (424) 1652 (494) 1748 (486) >0.05
Carbohydrate (g/day) 181 (29) 186 (25) 184 (25) 215 (25)d <0.05
Total sugars (g/day) 58 (28) 61 (22) 57 (17) 99 (25)e ≤0.001
Results expressed as mean (SD) or when data was not normally distributed as geometric mean (interquartile range).
The following subscripts indicate - a; p≤0.05 for baseline comparison between groups: b; p≤0.001 for baseline comparison between groups: c: p≤0.05 for within
group comparison: d; p≤0.001 for within group comparison.
Table 3 Serum, HDL2 and HDL3 carotenoid antioxidants pre and post F&V intervention
Antioxidant 1 Portion (n=35) 6 Portions (n=39) Trend for change
Pre Post Pre Post between groups
Serum (μmol/L)
α-carotene 0.028 (0.004) 0.028 (0.005) 0.029 (0.003) 0.032 (0.004)c 0.047
β-carotene 0.10 (0.03) 0.11 (0.04) 0.13 (0.02) 0.14 (0.02) 0.520
β-cryptoxanthin 0.03 (0.01) 0.03 (0.01) 0.04 (0.005) 0.05 (0.005)d 0.002
Lutein 0.12 (0.01) 0.12 (0.01) 0.12 (0.01) 0.15 (0.01)c 0.030
Lycopene 0.28 (0.04) 0.31 (0.05) 0.35 (0.05) 0.34 (0.04) 0.820
Zeaxanthin 0.03 (0.003) 0.03 (0.003) 0.03 (0.003) 0.04 (0.002) 0.020
HDL2 (nmol/L)
α-carotene 2.3 (0.3) 2.0 (0.4) 2.8 (0.3) 3.3 (0.7) 0.351
β-carotene 5.5 (1.1) 6.3 (1.5) 7.0 (1.1) 7.8 (0.1) 0.971
β-cryptoxanthin 2.0 (0.5) 1.7 (0.5) 1.9 (0.4) 2.8 (0.5)c 0.006
Lutein 5.5 (0.9) 5.9 (0.9) 5.9 (0.6) 7.6 (0.7)c 0.182
Lycopene 12.1 (1.2) 10.0 (1.1) 13.6 (1.3) 12.9 (1.2) 0.914
Zeaxanthin 3.1 (0.5) 2.8 (0.5) 2.9 (0.5) 2.7 (0.3) 0.826
HDL3 (nmol/L)
α-carotene 8.1 (1.2) 8.5 (1.2) 7.8 (1.1) 10.8 (1.7)d 0.008
β-carotene 23.4 (3.2) 25.9 (4.5) 19.8 (4.3) 25.7 (5.5)c 0.399
β-cryptoxanthin 14.1 (2.4) 13.8 (1.9) 13.3 (3.1) 17.6 (2.9)c 0.042
Lutein 6.3 (0.7) 6.5 (0.7) 6.6 (0.4) 7.2 (0.4)c 0.012
Lycopene 33.1 (4.3) 30.3 (3.5) 29.3 (4.1) 37.2 (4.8)c 0.016
Zeaxanthin 10.5 (0.9) 10.7 (0.9) 9.7 (1.1) 10.8 (1.2)c 0.166
Results expressed as mean (SEM) or when data was not normally distributed as geometric mean (interquartile range).
The following subscripts indicate - a; p≤0.05 for baseline comparison between groups: b; p≤0.001 for baseline comparison between groups: c; p≤0.05 for within
group comparison: d; p≤0.001 for within group comparison.
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PON-1 activity
Following intervention, serum-PON-1 activity was un-
changed in the ≥6- vs. 1-portion comparisons (p > 0.05;
Table 4), however, serum-PON-1 activity increased
by ~7% (p ≥ 0.001) following the ≥6-portion interven-
tion. In HDL2, PON-1 activity was unchanged in the
≥6- vs. 1-portion comparisons (p < 0.05) and following
the 1 and ≥6-portion interventions (p > 0.05 for both
comparisons). However, in HDL3, the activity of PON-1
significantly increased in the≥6- vs. 1-portion comparison
(p < 0.05), whichwas driven by the ~13% increase in its ac-
tivity following the ≥6-portion intervention (p ≤ 0.001),
despite the~4% increase in its activity following the 1-por-
tionintervention(p = 0.014).
LCAT activity
In serum, LCAT activity was unchanged in the ≥6- vs.
1-portion comparisons (p > 0.05; Table 4). However,
similarly to PON-1, the activity of serum-LCAT in-
creased by ~8% following the ≥6-portion intervention
(p = 0.025). In HDL2, the activity of LCAT was un-
changed in the ≥6- vs. 1-portion comparisons (p > 0.05)
and following the 1 and ≥6-portion interventions (p >
0.05 for both comparisons). However, the activity of
LCAT was increased in HDL3 in the ≥6- vs. 1-portion
comparison (p < 0.05), which was driven by the ~8% in-
crease in its activity following the ≥6-portion interven-
tion (p < 0.001).
hsCRP and SAA concentration
Following intervention, serum hsCRP and serum-,
HDL2- and HDL3-SAA were similar in the ≥6- vs.
1-portion comparisons (p < 0.05 for all comparisons;
Table 4) and although SAA decreased by ~32% following
the ≥6-portion intervention in HDL3, this was not sig-
nificant (p = 0.133).
Correlations between change in F&V intake, change in
carotenoid antioxidant levels and change in activity of
HDL-associated enzymes
Change in F&V intake was positively correlated with change
in HDL2-β-cryptoxanthin (r = 0.312, p = 0.047), HDL3
α-carotene (r = 0.416, p = 0.005), HDL3 β-cryptoxanthin
(r = 0.325, p = 0.032) and HDL3 lutein (r = 0.317, p = 0.036).
Additionally, change in HDL3 β-cryptoxanthin positively
correlated with change in HDL3-PON-1 activity (r = 0.258,
p = 0.043).
Discussion
Carotenoids and the influence of increased F&V intake
This study has demonstrated that increased F&V intake
augmented serum carotenoid levels in this subject popu-
lation, illustrating subject compliance and confirming
previous reports in healthy and T2D subjects [20]. In
addition, we have shown for the first time in a popula-
tion with T2D that this increase led to a concomitant
increase in the carotenoid content of HDL2 and
HDL3, which was particularly apparent for α-carotene,
Table 4 Serum, HDL2 and HDL3 PON-1 and LCAT activities and SAA and hsCRP concentrations pre and post F&V
intervention
Analyate 1 Portion (n=35) 6 Portions (n=39) Trend for change
Pre Post Pre Post between groups
Serum
PON-1 (U/mL) 25.78 (0.78)a 25.75 (0.78) 26.53 (0.81) 28.05 (0.79)d 0.155
LCAT ratio (470/390) 0.98 (0.04) 1.02 (0.03) 0.90 (0.02) 0.97 (0.02)c 0.562
SAA (μg/L) 21180 (6876,22894) 20926 (8898,22894) 21484 (6810,28645) 20464 (9020,31635) 0.399
hsCRP (mg/L) 2.30 (1.06,2.96) 2.19 (0.98,2.33) 2.17 (0.97,2.70) 2.34 (1.22,3.47) 0.527
HDL2
PON-1 (U/mL) 0.37 (0.03) 0.38 (0.04) 0.40 (0.04) 0.42 (0.04) 0.959
LCAT ratio (390/470) x10-3 5.25 (0.05) 5.26 (0.06) 5.31 (0.07) 5.34 (0.08) 0.996
SAA (μg/L) 1579 (214,1188) 1448 (242,1107) 1145 (204,1120) 1197 (254,1196) 0.228
HDL3
PON-1 (U/mL) 8.10 (0.21) 8.40 (0.20)c 8.54 (0.25) 9.51 (0.13)d 0.006
LCAT ratio (390/470) 0.89 (0.02) 0.90 (0.02) 0.87 (0.01) 0.94 (0.02)d 0.044
SAA (μg/L) 15834 (7549,21352) 17858 (5236,23360) 16211 (5007,24087) 12235 (4006,18120) 0.197
Results expressed as mean (SEM) or when data was not normally distributed as geometric mean (interquartile range).
PON-1 – paroxonase-1: LCAT – lecithin cholesterol acyltransferase: SAA – serum amyloid A
LCAT activity was read fluorometrically at 390 nm and 470 nm and expressed as a ratio of the two. These two wavelengths represent the LCAT substrate
hydrolysed and not hydrolysed. An increase in the ratio indicates increased LCAT activity.
The following subscripts indicate - a; p≤0.05 for baseline comparison between groups: b; p≤0.001 for baseline comparison between groups: c; p≤0.05 for within
group comparison; d; p≤0.001 for within group comparison.
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β-cryptoxanthin, lutein and lycopene in HDL3. Further-
more, this lycopene result confirms our previous find-
ings, where we identified that lycopene, which is the
most potent single oxygen quencher among the natural
carotenoids [21], increased in HDL2 and HDL3 following
a lycopene rich diet [11]. Thus we suggest that the in-
crease in the carotenoids identified in this current study
would enhance the antioxidant properties of HDL, simi-
larly to that reported in subjects with T2D following a
high polyphenol diet, where plasma malondialdehyde,
a frequently used indicator of lipid peroxidation [22]
decreased in subjects consuming this diet [23]. Further-
more, in support of our findings phylloquinone, a lipid-
soluble molecule that is found in green leafy plants,
improves markers related to insulin resistance and dia-
betes [24] and, due to its ability to accept electrons, con-
tributes to the antioxidant capacity of HDL, which we
suggest may also be the case for the increased caroten-
oids identified in this current study. In addition, a
Mediterranean-style diet has been suggested to be ad-
vantageous from a metabolic perspective in subjects with
T2D [25] and may even modulate genetic predisposition
in such subjects [26]. Thus, overall we suggest that the
increased antioxidants within the HDL subfractions, par-
ticularly HDL3, the subfraction more closely associated
with HDL’s antioxidant properties [27,28], would have
enhanced antiatherogenic potential in this T2D cohort.
PON-1 and LCAT activities and the influence of increased
F&V intake
This F&V intervention was also associated with signifi-
cant increases in the activities of both PON-1 and
LCAT, again confirming our previous findings following
a lycopene rich diet [11]. Therefore, as one of HDL’s
main antiatherogenic function is to inactivate peroxi-
dised lipids removed from apolipoprotein B-containing
lipoproteins, due to the proton donating properties of
PON-1 [29] and to a lesser extent LCAT [30], an in-
crease in the activities of these enzymes would be
thought of as antiatherogenic. Therefore, as the activity
of serum-PON-1 has been reported to be lower in sub-
jects with T2D [31], we have now shown that increased
F&V intake augmented its activity, in serum and particu-
larly in HDL3, in this T2D population, which was further
supported by the positive correlation between the con-
centration of β-cryptoxanthin and the activity of PON-1
in HDL3 (r = 0.258, p = 0.043). These findings are in sup-
port of previous studies, where quercetin and glabridin
were shown to protect PON-1 against copper-induced
oxidation [29], while pomegranate juice (a rich source of
carotenoids) was shown to increase its activity in healthy
male subjects [32]. Overall, we suggest that the increase
in the described antioxidants may have enhanced
PON-1’s proton donating properties and hence were
responsible for the increase in its activity, especially in
HDL3. We suggest that this increase in PON-1 activity
would enhance the antiatherogenic potential of HDL in
this T2D population.
With regards to LCAT, similarly to PON-1, this en-
zyme is mainly associated with HDL3, and its antioxi-
dant property is related to it proton donating property
[15,33]. Therefore, as the activity of LCAT has previ-
ously been reported to be decreased in subjects with
T2D [34], we have now shown that increased F&V in-
take augmented its activity within serum and particularly
in HDL3 in this T2D population. This increase in
LCAT’s activity may be related to the proton donating
capacities of the additional F&V derived antioxidants,
thus illustrating another antiatherogenic effect of in-
creased F&V intake.
BMI, inflammation and the role of increased F&V intake
We must address the fact that BMI increased in the sub-
jects randomised to the ≥6-portion intervention, in spite
of the diets being designed and appearing isocalorific in
both groups (p > 005). However, as both carbohydrate
and total sugars significantly increased following the ≥6
portion intervention, and as these compounds are read-
ily converted to fatty acids, this may have contributed to
the increased BMI in this group, although a point to
note is that these increases did not appear to influence
the long term marker of glycaemic control, namely
HbA1C, which was not different in the between group
comparisons. Unfortunately, this increase in BMI may
have negated a decrease in SAA, as there was only a
trend for this inflammatory marker to decrease in HDL3
following the ≥6-portion intervention (p = 0.133). This
was not consistent with previous non-reported findings
by our group, where SAA did decrease following
increased F&V intake, although in this study BMI
remained stable. Therefore, the increase in BMI (0.3 Kg/
m2) in the ≥6-portion group may have augmented SAA
release, especially as SAA is released chronically from
hypertrophic adipocytes [5]. Thus, the overall effect
would be that any SAA-lowering effects afforded by the
increased F&V intake would have been opposed by this
additional adipose tissue. Overall, this finding raises a
note of caution regarding the need to ensure that the
composition of a F&V intervention should be closely
monitored, to ensure that BMI remains stable. Neverthe-
less, this increase in BMI did not appear to impact on
the enzymes examined in this current study.
Finally, we must consider the non-significant (p = 0.295)
gender difference between the two groups at randomisa-
tion, where 20% of the subjects in the 1-portion interven-
tion were female, while females made up 38.5% of
the subjects in the ≥6-portion intervention. However,
although females usually attach greater importance to
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healthy eating [35], all subjects appeared to adhere to the
intervention group to which they were assigned, irrespect-
ive of gender. This was shown by the similar self-reported
F&V intake and changes in carotenoids in both genders
from each of the two groups (results not shown).
Conclusion
In subjects with T2D, increased F&V consumption re-
sulted in an increase in carotenoid levels and the activities
of PON-1 and LCAT, which was particularly apparent in
HDL3, which we suggest would augment the antioxidant
capabilities of this lipoprotein and would enhance its anti-
atherogenic potential. This study provides mechanistic
support for the effectiveness of increased F&V intake,
which may be a realistic lifestyle intervention to help lower
the risk of T2D and its associated CVD.
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